$MRZM
Marizyme Inc Stock $mrzm

$mrzm Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223041163 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$150.6K	$181.5K	$76.01K
YoY Change	57.39%	138.82%	104.22%
Cost Of Revenue	$48.23K	$50.99K	$15.50K
YoY Change	73.55%	228.96%	-15.58%
Gross Profit	$102.3K	$130.5K	$60.51K
YoY Change	50.77%	115.74%	220.84%
Gross Profit Margin	67.97%	71.91%	79.61%
Selling, General & Admin	$7.545M	$4.272M	$1.375M
YoY Change	471.48%	210.71%	-22.52%
% of Gross Profit	7373.65%	3272.57%	2272.3%
Research & Development	$387.1K	$492.2K	$708.2K
YoY Change	-43.14%	-30.5%	192.96%
% of Gross Profit	378.31%	377.06%	1170.42%
Depreciation & Amortization	$210.3K	$210.3K	$210.4K
YoY Change	-0.03%	-0.03%
% of Gross Profit	205.51%	161.08%	347.65%
Operating Expenses	$8.150M	$4.988M	$2.309M
YoY Change	268.54%	116.01%	30.11%
Operating Profit	-$8.048M	-$4.857M	-$2.233M
YoY Change	275.44%	117.52%	27.18%
Interest Expense	-$7.697M	-$7.406M	-$810.6K
YoY Change	569.92%	813.6%	1054.37%
% of Operating Profit
Other Income/Expense, Net	$18.70M	-$27.59M	$680.4K
YoY Change	400.09%	-4155.41%	250.72%
Pretax Income	-$9.766M	-$32.45M	-$1.553M
YoY Change	-58.56%	1990.01%	-4.86%
Income Tax
% Of Pretax Income
Net Earnings	-$9.766M	-$32.45M	-$1.553M
YoY Change	-58.56%	1990.01%	-4.86%
Net Earnings / Revenue	-6486.22%	-17875.49%	-2042.62%
Basic Earnings Per Share		-$0.71	-$0.04
Diluted Earnings Per Share	-$0.19	-$0.71	-$38.03K
COMMON SHARES
Basic Shares Outstanding	46.67M shares	45.67M shares	40.83M shares
Diluted Shares Outstanding		45.81M shares	40.83M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$148.5K	$474.9K	$1.182M
YoY Change	-70.94%	-59.83%	6992.08%
Cash & Equivalents	$148.5K	$474.9K	$1.182M
Short-Term Investments
Other Short-Term Assets	$699.4K	$661.4K	$839.8K
YoY Change	-37.87%	-21.25%	2299.49%
Inventory	$24.86K	$99.02K	$251.2K
Prepaid Expenses	$699.4K	$661.4K	$839.8K
Receivables	$60.28K	$43.22K	$54.23K
Other Receivables	$35.80K	$35.77K	$14.13K
Total Short-Term Assets	$968.8K	$1.314M	$2.342M
YoY Change	-50.45%	-43.87%	1333.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.50K	$12.50K	$12.61K
YoY Change	-0.36%	-0.9%	-98.92%
Goodwill	$5.416M	$7.191M	$7.191M
YoY Change	-24.68%	0.0%
Intangibles			$52.24M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$152.5K	$160.0K	$369.1K
YoY Change	-58.69%	-56.65%	-0.51%
Total Long-Term Assets	$21.05M	$35.61M	$61.38M
YoY Change	-42.7%	-42.0%	15.09%
TOTAL ASSETS
Total Short-Term Assets	$968.8K	$1.314M	$2.342M
Total Long-Term Assets	$21.05M	$35.61M	$61.38M
Total Assets	$22.02M	$36.92M	$63.73M
YoY Change	-43.1%	-42.06%	19.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.322M	$2.137M	$848.4K
YoY Change	70.06%	151.85%	-39.27%
Accrued Expenses	$434.1K	$431.4K	$420.9K
YoY Change	2.5%	2.5%	61.82%
Deferred Revenue
YoY Change
Short-Term Debt	$2.694M	$0.00	$213.6K
YoY Change		-100.0%
Long-Term Debt Due	$14.92M	$20.36M	$213.6K
YoY Change	1217.23%	9433.18%
Total Short-Term Liabilities	$20.60M	$48.67M	$1.606M
YoY Change	605.14%	2930.3%	-30.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$38.60K	$1.649M
YoY Change	-100.0%	-97.66%	818.76%
Other Long-Term Liabilities	$6.073M	$10.16M	$19.52M
YoY Change	-61.05%	-47.95%	80.98%
Total Long-Term Liabilities	$6.073M	$10.20M	$21.17M
YoY Change	-66.89%	-51.82%	93.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.60M	$48.67M	$1.606M
Total Long-Term Liabilities	$6.073M	$10.20M	$21.17M
Total Liabilities	$26.68M	$58.87M	$22.78M
YoY Change	25.44%	158.45%	71.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$151.3M	-$141.6M	-$62.43M
YoY Change	75.99%	126.78%
Common Stock	$131.8K	$46.67K	$40.83K
YoY Change	225.19%	14.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.661M	-$21.95M	$40.95M
YoY Change
Total Liabilities & Shareholders Equity	$22.02M	$36.92M	$63.73M
YoY Change	-43.1%	-42.06%	19.11%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$9.766M	-$32.45M	-$1.553M
YoY Change	-58.56%	1990.01%	-4.86%
Depreciation, Depletion And Amortization	$210.3K	$210.3K	$210.4K
YoY Change	-0.03%	-0.03%
Cash From Operating Activities	-$1.214M	-$1.153M	-$2.210M
YoY Change	-23.46%	-47.84%	65.27%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	887.5K	1.423M	1.348M
YoY Change	-2.98%	5.56%	-0.32%
NET CHANGE
Cash From Operating Activities	-1.214M	-1.153M	-2.210M
Cash From Investing Activities
Cash From Financing Activities	887.5K	1.423M	1.348M
Net Change In Cash	-326.5K	269.7K	-862.7K
YoY Change	-51.37%	-131.26%	-6025.27%
FREE CASH FLOW
Cash From Operating Activities	-$1.214M	-$1.153M	-$2.210M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	us-gaap	Royalty Expense RoyaltyExpense		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001413754
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent		usd
CY2022Q4	MRZM	Convertible Debt Original Issue Discount Current ConvertibleDebtOriginalIssueDiscountCurrent		usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	us-gaap	Royalty Expense RoyaltyExpense		usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q3	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt		usd
	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt		usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt		usd
	MRZM	Shares Issued As Part Of Confidential Settlement Agreement SharesIssuedAsPartOfConfidentialSettlementAgreement		usd
	MRZM	Shares Issued For Services SharesIssuedForServices		usd
	MRZM	Warrants Issued As Part Of Promissory Note Agreement WarrantsIssuedAsPartOfPromissoryNoteAgreement		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	MRZM	Warrants Cancelled In Debt Extinguishment WarrantsCancelledInDebtExtinguishment		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost		usd
CY2022Q3	MRZM	Debt Accretion Expenses DebtAccretionExpenses		usd
	MRZM	Debt Accretion Expenses DebtAccretionExpenses		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold		usd
CY2022Q3	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-53223
	dei	Entity Registrant Name EntityRegistrantName	MARIZYME, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5464863
	dei	Entity Address Address Line1 EntityAddressAddressLine1	555 Heritage Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 205
	dei	Entity Address City Or Town EntityAddressCityOrTown	Jupiter
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33458
	dei	City Area Code CityAreaCode	(561)
	dei	Local Phone Number LocalPhoneNumber	935-9955
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	46666760	shares
CY2023Q3	us-gaap	Cash Cash	474944	usd
CY2022Q4	us-gaap	Cash Cash	510865	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	43218	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	87801	usd
CY2023Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	35773	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15310	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	661394	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1125761	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	99019	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	215566	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	1314348	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1955303	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12500	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12545	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1198207	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1485023	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27044141	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27675020	usd
CY2023Q3	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	129989	usd
CY2022Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	339091	usd
CY2023Q3	us-gaap	Deposit Assets DepositAssets	30000	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	30000	usd
CY2023Q3	us-gaap	Goodwill Goodwill	7190656	usd
CY2022Q4	us-gaap	Goodwill Goodwill	7190656	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	35605493	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	36732335	usd
CY2023Q3	us-gaap	Assets Assets	36919841	usd
CY2022Q4	us-gaap	Assets Assets	38687638	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2136592	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1365443	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	240916	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1132829	usd
CY2023Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	19124357	usd
CY2023Q3	MRZM	Convertible Debt Original Issue Discount Current ConvertibleDebtOriginalIssueDiscountCurrent	993785	usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	25555092	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	431435	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	423495	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	48669274	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2921767	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	766772	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1061528	usd
CY2023Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	38596	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	2751633	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4823725	usd
CY2023Q3	MRZM	Contingent Liabilities ContingentLiabilities	9395000	usd
CY2022Q4	MRZM	Contingent Liabilities ContingentLiabilities	9707000	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	10200368	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	18343886	usd
CY2023Q3	us-gaap	Liabilities Liabilities	58869642	usd
CY2022Q4	us-gaap	Liabilities Liabilities	21265653	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46666760	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46666760	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40528191	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40528191	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	46666	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	40528	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	119574221	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	103370890	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141570688	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85989433	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-21949801	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17421985	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36919841	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38687638	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	181535	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	76012	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	495248	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	137821	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	50989	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	15503	usd
	us-gaap	Cost Of Revenue CostOfRevenue	139875	usd
	us-gaap	Cost Of Revenue CostOfRevenue	26528	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	130546	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	60509	usd
	us-gaap	Gross Profit GrossProfit	355373	usd
	us-gaap	Gross Profit GrossProfit	111293	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	921552	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	303574	usd
	us-gaap	Professional Fees ProfessionalFees	1818202	usd
	us-gaap	Professional Fees ProfessionalFees	1721479	usd
CY2023Q3	us-gaap	Salaries And Wages SalariesAndWages	329564	usd
CY2022Q3	us-gaap	Salaries And Wages SalariesAndWages	330221	usd
	us-gaap	Salaries And Wages SalariesAndWages	931536	usd
	us-gaap	Salaries And Wages SalariesAndWages	2147967	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	492235	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	708220	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1789625	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3297986	usd
CY2023Q3	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	86132	usd
CY2022Q3	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	271517	usd
	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	457860	usd
	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	1664191	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	210293	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	210361	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	630924	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	631083	usd
CY2023Q3	us-gaap	Royalty Expense RoyaltyExpense	13014	usd
	us-gaap	Royalty Expense RoyaltyExpense	211262	usd
CY2023Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2934966	usd
CY2022Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	469656	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	6310039	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1478726	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	4987756	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2293549	usd
	us-gaap	Operating Expenses OperatingExpenses	12149448	usd
	us-gaap	Operating Expenses OperatingExpenses	10941432	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4857210	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2233040	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11794075	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10830139	usd
CY2023Q3	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	7405668	usd
CY2022Q3	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	810598	usd
	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	22527538	usd
	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	1640368	usd
CY2023Q3	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	-1678000	usd
CY2022Q3	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	1491000	usd
	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	312000	usd
	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	-2131000	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-14454397	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-14454397	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-80001	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-764683	usd
CY2023Q3	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt	-3974993	usd
	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt	-6352562	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-27593059	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	680402	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43787180	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3771368	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-32450269	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1552638	usd
	us-gaap	Net Income Loss NetIncomeLoss	-55581255	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14601507	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.28
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45812412	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45812412	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40828188	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40828188	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43270975	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43270975	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40762254	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40762254	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	47690332	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	716432	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2969916	usd
CY2022Q1	MRZM	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	3000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-6124885	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	45254795	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	676242	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2341659	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-6923984	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	41348712	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	271517	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	880000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1552638	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	40947591	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17421985	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	210966	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	153600	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2554584	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15231967	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	160762	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	223486	usd
CY2023Q2	MRZM	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	265216	usd
CY2023Q2	MRZM	Adjustments To Additional Paid In Capital Issuance Of Warrants On Debt Extinguishment AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsOnDebtExtinguishment	19058426	usd
CY2023Q2	MRZM	Adjustments To Additional Paid In Capital Issuance Of Warrants On Promissory Note AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsOnPromissoryNote	1333128	usd
CY2023Q2	MRZM	Stock Issued During Period Warrants Cancelled In Debt Extinguishment StockIssuedDuringPeriodWarrantsCancelledInDebtExtinguishment	-8426927	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-20576402	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7269656	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7269656	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	86132	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	210000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2934680	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-32450269	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-21949801	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-21949801	usd
	us-gaap	Net Income Loss NetIncomeLoss	-55581255	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14601507	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	630924	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	631083	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	457860	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1664191	usd
	MRZM	Interest And Accretion Expenses InterestAndAccretionExpenses	22527538	usd
	MRZM	Interest And Accretion Expenses InterestAndAccretionExpenses	1637951	usd
	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	312000	usd
	MRZM	Issuance Of Warrants For Services IssuanceOfWarrantsForServices	-2934680	usd
	MRZM	Issuance Of Warrants For Services IssuanceOfWarrantsForServices	-1850533	usd
	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	-2131000	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	14454397	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-764683	usd
	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt	-6352562	usd
	MRZM	Shares Issued As Part Of Confidential Settlement Agreement SharesIssuedAsPartOfConfidentialSettlementAgreement	153600	usd
	MRZM	Shares Issued For Services SharesIssuedForServices	168000	usd
	MRZM	Warrants Issued As Part Of Promissory Note Agreement WarrantsIssuedAsPartOfPromissoryNoteAgreement	1333128	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-24120	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	18402	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-464367	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	582649	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-116547	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	228834	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1852865	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-740034	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	187097	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-1009368	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3470887	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9266036	usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	2334000	usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	6500743	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	265216	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1000000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	164250	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	127798	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3434966	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6375945	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-35921	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2890091	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	510865	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4072339	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	474944	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1182248	usd
	MRZM	Derivative Liabilities And Debt Discount Issued In Connection With Convertible Notes DerivativeLiabilitiesAndDebtDiscountIssuedInConnectionWithConvertibleNotes	25555092	usd
	MRZM	Derivative Liabilities And Debt Discount Issued In Connection With Convertible Notes DerivativeLiabilitiesAndDebtDiscountIssuedInConnectionWithConvertibleNotes	2438379	usd
	MRZM	Warrants And Debt Discount Issued In Connection With Convertible Notes WarrantsAndDebtDiscountIssuedInConnectionWithConvertibleNotes	19403385	usd
	MRZM	Warrants And Debt Discount Issued In Connection With Convertible Notes WarrantsAndDebtDiscountIssuedInConnectionWithConvertibleNotes	4341042	usd
	MRZM	Settlement Of Notes Payable With Convertible Notes SettlementOfNotesPayableWithConvertibleNotes	2264133	usd
	MRZM	Settlement Of Notes Payable With Convertible Notes SettlementOfNotesPayableWithConvertibleNotes	278678	usd
	MRZM	Warrants Cancelled In Debt Extinguishment WarrantsCancelledInDebtExtinguishment	8426927	usd
	us-gaap	Stock Issued1 StockIssued1	84140	usd
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	103291	usd
	us-gaap	Payments For Rent PaymentsForRent	324544	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141570688	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85989433	usd
CY2023Q3	MRZM	Working Capital WorkingCapital	47354926	usd
CY2022Q4	MRZM	Working Capital WorkingCapital	966464	usd
CY2023Q3	us-gaap	Cash Cash	474944	usd
CY2022Q4	us-gaap	Cash Cash	510865	usd
CY2023Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1203537	usd
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	535717	usd
CY2020Q4	us-gaap	Area Of Land AreaOfLand	10300	sqft
CY2022Q2	us-gaap	Area Of Land AreaOfLand	3053	sqft
CY2023Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y9M29D
CY2023Q3	us-gaap	Payments For Rent PaymentsForRent	81502	usd
	us-gaap	Payments For Rent PaymentsForRent	274004	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zF7lMHgXoSw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zqDiFIDiDan2">Use of Estimates</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, derivative liabilities and contingent liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	MRZM	Midrange Average Estimated Interest Rate MidrangeAverageEstimatedInterestRate	0.206	pure
CY2023Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	1262000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	466000	usd
CY2022Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	516000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	1288000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5868000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5402000	usd
CY2020Q4	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	five-and-a-half-year lease agreement
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1198207	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1485023	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	431435	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	423495	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	766772	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1061528	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1198207	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1485023	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	105874	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	434082	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	444934	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	266034	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1250924	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	52717	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1198207	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29142745	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-2098604	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27044141	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	53492745	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1467725	usd
CY2022Q4	MRZM	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	-24350000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27675020	usd
CY2023Q3	us-gaap	Goodwill Goodwill	7190656	usd
CY2022Q4	us-gaap	Goodwill Goodwill	7190656	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	52866192	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	24350000	usd
CY2022	MRZM	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	841172	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27675020	usd
	MRZM	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	630879	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27044141	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4260594	shares
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6692765	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4180071	shares
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6500743	usd
	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	684682	usd
	MRZM	Adjustments To Additional Paid In Capital Issuance Of Warrants On Debt Extinguishment AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsOnDebtExtinguishment	19403385	usd
CY2023Q3	MRZM	Interest And Accretion Expense InterestAndAccretionExpense	6418297	usd
	MRZM	Interest And Accretion Expense InterestAndAccretionExpense	13705189	usd
CY2022Q3	MRZM	Interest And Accretion Expense InterestAndAccretionExpense	805849	usd
	MRZM	Interest And Accretion Expense InterestAndAccretionExpense	1622730	usd
CY2023Q2	MRZM	Accrued Interest Payable Price Per Share AccruedInterestPayablePricePerShare	0.10
CY2023Q3	MRZM	Debt Accretion Expenses DebtAccretionExpenses	843699	usd
	MRZM	Debt Accretion Expenses DebtAccretionExpenses	993785	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46666760	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46666760	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40528191	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40528191	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	400000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3650943	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.24
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M2D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	400000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.20
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	62502	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	62498	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.25
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3925943	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.33
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y21D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3925943	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.33
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M21D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3582886	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.28
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y7D
	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	295750	usd
	MRZM	Share Based Compensation Arrangements By Share Based Payment Award Non Options Derivative Liabilities Extinguished ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsDerivativeLiabilitiesExtinguished	0.10
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	86132	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	457860	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	271517	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1664191	usd
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	216000	usd
CY2022Q3	us-gaap	Salaries And Wages SalariesAndWages	30000	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	250000	shares
CY2021Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.50
CY2019Q3	MRZM	Royalties Percentage RoyaltiesPercentage	0.10	pure

Files In Submission

Name	View Source	Status
mrzm-20230930_def.xml	Edgar Link	unprocessable
0001493152-23-041163-index-headers.html	Edgar Link	pending
0001493152-23-041163-index.html	Edgar Link	pending
0001493152-23-041163.txt	Edgar Link	pending
0001493152-23-041163-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrzm-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mrzm-20230930_cal.xml	Edgar Link	unprocessable
mrzm-20230930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
mrzm-20230930_lab.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRZM
Marizyme Inc Stock $mrzm

2023 Q4 Form 10-Q Financial Statement

#000149315223041163 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRZM Marizyme Inc Stock $mrzm

2023 Q4 Form 10-Q Financial Statement

#000149315223041163 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRZM
Marizyme Inc Stock $mrzm